FindTrial
Sign In

The use of AKITA® JET in cystic fibrosis: Treatment protocol and impact on lung function decline, lung clearance index and imaging.

The use of AKITA® JET in cystic fibrosis: Treatment protocol and impact on lung function decline, lung clearance index and imaging.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25660
Enrollment
50
Registered
2012-09-11
Start date
2012-09-06
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis Inhalation therapy AKITA® JET nebuliser

Interventions

Patients will use the AKITA® JET inhalation device to inhale their medication for 3 months.

Sponsors

University Hospital Brussels, Cystic Fibrosis Reference Center Laarbeeklaan 101, 1090 Jette
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with cystic fibrosis (6-65 years); 2. Treated with inhalation medication; 3. Never used AKITA® JET before.

Exclusion criteria

Exclusion criteria: 1. Patients younger than 6 years; 2. Acute pulmonary exacerbation at day of inclusion.

Design outcomes

Primary

MeasureTime frame
1. Quality of Life; 2. FEV1; 3. LCI; 4. CT Bhalla score.—

Contacts

Public ContactJ. Willekens

Laarbeeklaan 101

julie.willekens@uzbrussel.be

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)